menu
    • menu

    Company profile for EG 427

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. The company develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic, and localized diseases, enabling physician...
    EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. The company develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic, and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EG 427France Flag
    Country
    Country
    France
    Address
    Address
    29 rue du Faubourg Saint-Jacques, 75014 Paris
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eg427.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eg427/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EG 427 Receives US FDA Fast Track Designation for EG110A
    EG 427 Receives US FDA Fast Track Designation for EG110A

    06 Oct 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-10-06/eg-427-receives-us-fda-fast-track-designation-for-eg110a-dna-medicine-in-neurogenic-bladder-patients

    PHARMAWEB
    06 Oct 2025
    Share Share
    EG 427 Reports Promising Data for EG110A in Neurogenic Bladder
    EG 427 Reports Promising Data for EG110A in Neurogenic Bladder

    02 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-02/eg-427-announces-compelling-initial-topline-clinical-results-with-eg110a-dna-medicine-in-neurogenic-bladder-patients

    PHARMIWEB
    02 Oct 2025
    Share Share
    EG 427 Treats First Patient With EG110A For Neurogenic Bladder
    EG 427 Treats First Patient With EG110A For Neurogenic Bladder

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/27/3033525/0/en/Significant-milestone-reached-for-EG-427-with-first-patient-treated-with-EG110A-first-non-replicative-herpes-vector-based-genetic-medicine-for-the-treatment-of-neurogenic-bladder.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share
    EG 427 Raises €27M In Series B For Clinical Study & Platform Expansion
    EG 427 Raises €27M In Series B For Clinical Study & Platform Expansion

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/20/3029316/0/en/EG-427-raises-27-million-in-successful-Series-B-co-led-by-Andera-Partners-and-Bpifrance-to-finance-on-going-clinical-study-and-platform-development.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    1st gene therapy for prevalent neurology pathologies receives FDA IND clearance
    1st gene therapy for prevalent neurology pathologies receives FDA IND clearance

    24 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/24/2902739/0/en/First-gene-therapy-for-prevalent-pathologies-in-neurology-receives-FDA-IND-clearance-EG-427-initiating-first-in-human-clinical-study.html

    GLOBENEWSWIRE
    24 Jun 2024
    Share Share
    EG427 Announces New Preclinical Results from Multiple Studies of EG110A
    EG427 Announces New Preclinical Results from Multiple Studies of EG110A

    04 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/04/2803917/0/en/EG427-Announces-New-Preclinical-Results-from-Multiple-Studies-of-EG110A-in-Neurogenic-Detrusor-Overactivity-NDO-and-Overactive-Bladder-OAB.html

    GLOBENEWSWIRE
    04 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search